ScholarX: LEE, JEE YUN

Detailed Information

LEE, JEE YUN (이지연)

Medicine (Medicine)

Research Area: Precision Oncology, Precision Immunooncology, Phase I, Biomarker discovery, Precision Oncology, Precision Immunooncology, Phase I, Biomarker discovery

Tel 02-3410-1779
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Gastric cancer:42||gastric cancer:30||Chemotherapy:18||Colorectal cancer:17||Prognosis:14||2:13||chemotherapy:11||immunotherapy:10||Stomach neoplasms:10||Melanoma:10||Capecitabine:9||PDL1:8||Biomarker:8||3:8||Immunohistochemistry:8||Oxaliplatin:7||KRAS:7||Nonsmall cell lung cancer:7||Pembrolizumab:7||Simvastatin:7||HER2:6||Recurrence:6||prognosis:6||biomarker:6||Radiotherapy:6||S1:6||MET:5||Biomarkers:5||nextgeneration sequencing:5||colorectal cancer:5||Gemcitabine:5||melanoma:5||Quality of life:5||Immunotherapy:5||pembrolizumab:5||Pancreatic cancer:5||paclitaxel:5||Pazopanib:5||tumor mutational burden:4||cisplatin:4||Immune checkpoint inhibitor:4||nivolumab:4||NGS:4||Docetaxel:4||Irinotecan:4||Advanced gastric cancer:4||Metastasis:4||Bevacizumab:4||pancreatic cancer:4||Stomach neoplasm:4||PIK3CA mutation:4||survival:4||capecitabine:4||Cisplatin:4||gemcitabine:4||Erlotinib:4||Prognostic factors:3||nonsmall cell lung cancer:3||Mutation:3||biliary tract cancer:3||Colorectal neoplasms:3||BRAF mutation:3||Survival:3||ramucirumab:3||radiotherapy:3||pharmacokinetics:3||Advanced gastric cancer (AGC):3||Gastric:3||KIT mutation:3||CDK4/6 inhibitor:3||Sarcopenia:3||Sarcoma:3||Biliary tract cancer:3||Paclitaxel:3||Nivolumab:3||Rectal cancer:3||Palliative chemotherapy:3||Everolimus:3||Gefitinib:3||Nextgeneration sequencing:3||Next generation sequencing:3||cancer:3||Microsatellite instability:3||Regorafenib:3||ERBB2:3||Rectal neoplasms:3||Gastric carcinoma:3||microsatellite instability:3||Epidermal growth factor receptor:3||Lung cancer:3||Cetuximab:3||Esophageal squamous cell carcinoma:3||Amplification:3||Predictive marker:3||epidermal growth factor receptor:3||Patientderived cell:3||Adenocarcinoma:2||gastric:2||therapy:2||Epstein–Barr virus:2||MMR:2||TP53:2||MSI:2||Hedgehog pathway:2||gefitinib:2||gene expression:2||Concurrent chemoradiotherapy:2||vemurafenib:2||Target:2||Hepatocellular carcinoma:2||genomics:2||1:2||Targeted therapy:2||Therapy:2||Pemetrexed:2||Angiogenesis:2||Transcriptome:2||3620:2||Trastuzumab:2||MerTK:2||Carcinoma:2||Adjuvant:2||Phase I study:2||Tumor:2||Breast neoplasms:2||immune checkpoint inhibition:2||Metastatic:2||6:2||Metastatic colorectal cancer:2||FGFR2:2||FGFR2 amplification:2||immunohistochemistry:2||Prediction:2||Predictive:2||inflammation:2||Uterus:2||242:2||Preoperative chemoradiotherapy:2||Adjuvant therapy:2||liquid biopsy:2||Imatinib:2||1880:2||lung:2||FOLFOX:2||Wholeexome sequencing:2||Prognostic factor:2||Prognostic model:2||metastasis:2||metastatic cancer:2||Immune checkpoint inhibitors:2||adjuvant therapy:2||Programmed deathligand 1:2||advanced gastric cancer:2||Incidence:2||Chemoradiotherapy:2||RAD001:2||ARID1A:2||neuroendocrine tumors:2||angiogenesis:2||Intraperitoneal administration:2||ATM:2||noncutaneous melanoma:2||RICTOR:2||Doxorubicin:2||AZD2014:2||overall survival:2||EGFR:2||oxaliplatin:2||Radiation effects:2||Radiation therapy:2||Ramucirumab:2||NanoString:2||KIT amplification:2||3D culture:2||cMET:2||pazopanib:2||Neuroendocrine tumor:2||Neurotoxicity:2||Gastroenteropancreatic neuroendocrine tumor (GEPNET):2||ERCC1:2||Nilotinib:2||SMO:2||colon cancer:2||colorectal carcinoma:2||6136156463281:2||Acral melanoma:2||5:2||Endometrium:2||refractory cancer:2||Leukopenia:2||Liposarcoma:2||Soft tissue sarcoma:2||Liver metastasis:2||Sorafenib:2||doxorubicin:2||Colorectal cancer (CRC):2||secondline:2||Lymphoma:2||drugdrug interactions:2||MAPK15:2||Stomach:2||Stomach cancer:2||sirolimus:2||Surgery:2||stomach neoplasm:2||targeted therapy:2||Cancer:2||Highthroughput screening (HTS):1||Histological type:1||Histology:1||Human epidermal growth factor 2 (HER2):1||Humanized:1||Hyperammonemia:1||IHC screen:1||IKK epsilon:1||IMC001:1||Ifosfamide:1||Imatinib mesylate:1||Immune:1||Immune genes:1||Immunohistochemical stain:1||Induced hyperthermia:1||Inflammation:1||Initial dose:1||Interleukin4:1||Intrathecal chemotherapy:1||Ipilimumab:1||Kras:1||KIT:1||KIT amplificati:1||KIT gene:1||KML001:1||KRAS mutation:1||Ki67 proliferation index:1||Ki67 index:1||Korean:1||Korean ethnicity:1||L1:1||LAG3:1||LRP1B:1||LY573636:1||LargeB cell:1||Lateral lymph node:1||Lateral pelvic recurrence:1||Leptomeningeal:1||Leptomeningeal metastasis:1||Liver:1||Liver kinase B1:1||Lung:1||Lung metastasis:1||Lymph node:1||MDM2:1||MEK:1||MET alterations:1||MET amplification:1||MET exon 14 skipping:1||MET kinase inhibitors:1||MET monoclonal antibodies:1||MSI high:1||MSIH:1||MSS:1||MTHFR:1||Macrocytosis:1||Maintenance:1||Maintenance therapy:1||Malignant melanoma:1||Malignant mixed mullerian tumors (MMMT):1||Masaoka&apos:1||Maximum tolerated dose:1||Mesorectalfascia:1||Metabolic tumor volume:1||Metastases:1||Metastatic cancer:1||Metatstatic colorectal cancer:1||Methylation array:1||Microarray gene expression:1||Microfluidic chip:1||Microsatellite instabilityhigh:1||Microsatellite status:1||Minnelide:1||Mismatch repair protein:1||Moderately emetogenic chemotherapy:1||Molecular:1||Molecular profiling:1||Molecular screening:1||Molecular subtype:1||Monocarboxylate transporter:1||Monoclonal:1||Mouse:1||Mucosal melanoma:1||Multiplexing:1||NMethylNnitrosoguanidine human osteosarcoma transforming gene (MET):1||Nacetylcysteine:1||Nglycan:1||NK/Tcell lymphoma:1||NONMEM:1||NSCLC:1||NTRK:1||NTRK1 rearrangement:1||Nanostring:1||Neoadjuvant:1||Neoadjuvant chemoradiotherapy:1||Neoadjuvant th:1||Neoadjuvant treatment:1||Neoplasm:1||Neoplasm staging:1||Neoplasms:1||Neuroendocrine neoplasm:1||Neversmokers:1||NextGeneration Sequencing:1||Nextgeneration sequencing (NGS):1||Nomogram:1||Nomograms:1||Nonsmall cell l:1||Nonsmallcell lung cancer:1||Nontransitional cell carcinoma:1||Novel fusion:1||Offlabel use:1||Ointment:1||Outcomes:1||Ovarian metastasis:1||Ovarian metastatectomy:1||Oxaliplatinresistance:1||P:1||Pglycoprotein:1||PARP:1||PD1:1||PD1 inhibitor:1||PET:1||PIK3CA amplification/mutation:1||PIK3CAE542K:1||PRKCI:1||PRO007:1||PTCH1:1||PTEN loss:1||PTEN mutation:1||Pain:1||Palbociclib:1||Palliative treatment:1||Pancreatic cancer subtypes:1||Pathologic complete response:1||Pathology:1||Patient selection:1||Patientderived cells:1||Patientderived tumor spheroids:1||Patterns of failure:1||Pediatrictype sarcoma:1||Peripheral Tcell lymphoma:1||Peritoneal seeding:1||Pharmacogenetics:1||Pharmacogenomics:1||Pharmacokinetics:1||Phase 1:1||Phase I:1||Phase II:1||Phase II clinical trial:1||Platinum:1||Pleomorphic carcinoma:1||Population characteristics:1||Postoperative chemoradiotherapy:1||Precision medicine:1||Predictive factor:1||Predictors:1||Preoperative:1||Primary resistance:1||Primitive neuroectodermal tumor family:1||Prog:1||Prognostic:1||Prognostic marker:1||Programmed Cell Death 1 Receptor:1||Programmed cell death 1:1||Programmed cell death ligand 1 expression:1||Programmed death ligand 1:1||Programmed death ligand 1 expression:1||Programmed deathligand 1 (PDL1):1||Pulmonary embolism:1||Pulmonary metastasectomy:1||Pulmonary metastasis:1||RAF inhibitor:1||RAF1 aberration:1||RAS signature:1||RET fusion:1||RNA Editing:1||RNF11:1||ROS1rearranged gastric adenocarcinoma:1||RT:1||RTPCR:1||Radi:1||Randomized controlled trial:1||Randomized trial:1||Rapid infusion:1||Ras mutation:1||Realtime polymerase chai:1||Realworld evidence:1||Refractory gastric cancer:1||Renal cell carcinoma:1||Renal insufficiency:1||Response:1||Retrospective study:1||Rhabdomyosarcoma:1||RhoA:1||Ribonucleic acid sequencing:1||Risk:1||SAIT301:1||SLC22A18:1||SLC34A2RO:1||Salvage therapy:1||Salvage treatment:1||Second line chemotherapy:1||Sequencing:1||Serine/threonine kinase 11:1||Seru:1||Sex:1||Sidedness:1||Singlecell RNA sequencing:1||Skeletalrelated event:1||Skin:1||Skin reaction:1||Smoking status:1||Solid tumor:1||Solid tumors:1||Somatic:1||Somatic mutation:1||Somatostatin receptor 2:1||Spinal cord compression:1||Squamous cell:1||Src kinase:1||Stability:1||Stem cells:1||Sunitinib, dose, toxicity, response:1||Survey:1||Survival benefit:1||Surviving:1||Synthetic 3hydroxy3methyglutaryl coenzyme A (HMGCoA):1||TAS102:1||TAS102 plus bevacizumab:1||TBK1:1||TCGA molecular subtype:1||TFE3:1||TMB:1||TP53 mutation:1||TPK1:1||TRAP:1||TRKA immunohistochemistry:1||TSC2 gene:1||TSU68:1||TYMS:1||Tamoxifen:1||Tanibirumab:1||Targeted panel sequencing:1||Targeted sequencing:1||The effect of bevacizumab was not different between LC and RC and between MSS and the MSIH tumors:1||Therapeutic target:1||Thymidylate synthase:1||Toxicity:1||Transdermal granisetron:1||Treatment outcome:1||Treatment strategy:1||TruSight™ Oncology 500 assay:1||Tuberculosis:1||Tuberous sclerosis complex:1||Tubulovillous adenoma:1||Tumor mutation burden (TMB):1||Tumour mutational burden:1||Unfavorable:1||Unknown primary:1||Urinary bladder neoplasms:1||Urothelial:1||Urothelial carcinoma:1||Ussing chamber:1||Uterine Cervical Neoplasms:1||VEGFR2 inhibitor:1||Vandetanib:1||Vismodegib:1||Vortex keratopathy:1||WHO classification:1||WHO histologic classification:1||White ethnicity:1||Whole exome sequencing:1||Whole exome sequencings:1||Whole transcriptome sequencing:1||Wholegenome sequencing:1||Wholetranscriptome sequencing:1||XELIRI/FOLFIRI chemotherapy:1||XELOX:1||Xenograft model:1||actionable mutations:1||adenocarcinoma:1||adiposity:1||adjuvant:1||adjuvant treatment:1||advanced gastric cancer (AGC):1||allinone:1||allogeneic:1||amphiregulin:1||amplification:1||anaplastic lymphoma kinase (ALK) rearrangement:1||and Tumor burden:1||anemia:1||angiosarcoma:1||antiangiogenesis:1||antiangiogenic agent:1||apoptosis:1||arsenical:1||ascites:1||ataxia telangiectasia and Rad3 related protein (ATR):1||atezolizumab:1||autologous HSCT:1||autologous hematopoietic stem cell transplantation:1||avelumab:1||basal tone:1||basket study:1||bevacizumab:1||bladder cancer:1||bone marrowderived stromal cells:1||breast cancer:1||c:1||cJun:1||cerbB2 gene:1||cell adhesion molecules:1||cell free DNA (cfDNA):1||cellfree DNA (cfDNA):1||ceralasertib:1||cfDNA:1||checkpoint inhibitor:1||chemoradiation:1||chemoradiotherapy:1||cholangiocarcinoma:1||chronic GVHD:1||circulating tumor DNA:1||claudin 18.2:1||clinical grading:1||clinical sequencing:1||clinical trial:1||clinical trials, phase II as topic:1||coamplification:1||coactivation:1||colorectal cancer (CRC):1||combination therapy:1||combined positive score:1||combined treatment:1||copy number alteration:1||critical presentations:1||crizotinib:1||cutoff points:1||cytology:1||c‑KIT mutation:1||dRecurrence:1||dabrafenib/trametinib:1||dacarbazine:1||deep vein thrombosis:1||diabetic stomach:1||diagnostic assay:1||diffuse large B cell lymphoma:1||digital sequencing:1||digoxin:1||docetaxe:1||docetaxel:1||docetaxelPM:1||droplet digital PCR (ddPCR):1||drug eruption:1||drug resistant:1||durvalumab:1||echocardiography:1||endoscopy:1||entrectinib:1||epigenetic alternate promoter:1||epithelial–mesenchymal transition (EMT):1||erlotinib:1||etoposide:1||firstline treatment:1||frameshift mutation:1||frequency:1||fusion:1||gall bladder cancer:1||gastrectomy:1||gastric carcinoma:1||gastric muscle:1||gastroenteropancreatic neuroendocrine neoplasm (GEPNEN):1||gastroenteropancreatic neuroendocrine carcinoma (GEPNEC)s:1||gastroenteropancreatic neuroendocrine neoplasm:1||gastrointestinal cancer:1||gastrointestinal malignancies:1||gastrointestinal neoplasms:1||gastrointestinal tract:1||gastrooesophageal junction cancer:1||gene fusions:1||gene rearrangements:1||gene signature:1||genetic diagnosis:1||genome instability:1||genomewide association:1||genomic:1||genomic test:1||graft vs. host disease:1||head and neck cancers:1||hematopoietic stem cell transplantation:1||hepatocellular carcinoma:1||hepatocyte growth factor:1||highthroughput drug screening:1||highthroughput experimentation:1||highthroughput s:1||highthroughput screening (HTS):1||human colon:1||human epidermal growth factor receptor 2 (HER2):1||hyaluronan:1||idiopathic thrombocytopenic purpura:1||ifosfamide:1||imatinib:1||immune check point inhibitor:1||immune checkpoint blockade:1||immune checkpoint inhibitor:1||immune checkpoint inhibitors:1||immune infiltrates:1||immune microenvironment:1||immune resistance:1||immunohistochemistr:1||immunosuppressive treatment:1||infection:1||intensive chemotherapy:1||intestinal lymphoma:1||intratumoral heterogeneity:1||intravenous immunoglobulins:1||landscape:1||leiomyosarcoma:1||leukocyte count:1||liver cancer:1||lovastatin:1||mTOR:1||mTOR inhibitor:1||mTORC1/2:1||mammalian target of rapamycin inhibitor (mTOR inhibitor):1||marginal zone B cell lymphoma:1||marginal zone Bcell lymphoma:1||mesenchymal:1||metastatic colorectal cancer:1||metastatic melanoma:1||metastatic solid tumor:1||microenvironment:1||microfluidics:1||mismatch repair deficiency (dMMR):1||molecular profiling:1||molecular targeted therapy:1||molecularly targeted agents:1||monotherapy:1||neoadjuvant chemotherapy:1||neoadjuvant therapy:1||neuroendocrine carcinoma:1||neuroendocrine carcinoma (NEC):1||neuroendocrine tumor:1||neuroendocrine tumor (NET):1||neuropathy:1||next generation sequencing:1||nextgeneration sequencing (NGS):1||nongastric:1||obesity:1||oncogene:1||oncology:1||organonachip:1||outcome:1||overall survival analysis:1||p53:1||pSTAT3:1||paclitaxel/carboplatin:1||pantumor:1||pancreatic adenocarcinoma:1||panel sequencing:1||pathologic differentiation:1||pathology:1||pathway:1||patientderived cancer cells (PDCs):1||patientderived cell (PDC):1||patientderived cells:1||patientderived tumor cell:1||patientderived tumor cells:1||pemetrexed:1||peritoneal mesothelioma:1||personalized medicine:1||pharmacodynamics:1||phase 3 chemotherapy:1||phase I:1||phosphorylated signal transducer and activator of transcription 3:1||platelet count:1||platinum:1||postremission therapy:1||precision:1||precision medicine:1||preclinical model:1||prediction:1||predictive biomarker:1||predictor:1||primary tumor site:1||prognostic factor:1||prognostic index:1||prognostic model:1||programmed cell death 1 receptor:1||programmed cell deathligand 1 (PDL1):1||programmed death 1/programmed death ligand 1:1||programmed deathligand 1:1||programmed deathligand 1 (PDL1):1||proof of concept:1||prostate carcinoma:1||pulmonary artery:1||pulmonary embolism:1||radiation therapy:1||radiomics:1||radiosensitivity:1||reactive oxygen species:1||realtime PCR:1||rectal neoplasm:1||recurrence:1||regional difference:1||regorafenib:1||response rate:1||s sarcoma:1||s staging system:1||safety:1||salivary duct carcinoma:1||salvage chemotherapy:1||salvage regimen:1||salvage treatment:1||saracatinib (AZD0530):1||sarcopenia:1||scoring model:1||secondline chemotherapy:1||secondary maligna:1||segmental heterogeneity:1||selumetinib:1||senescence:1||sex hormone:1||simvastatin:1||singlenucleotide variants:1||small cell lung cancer:1||solid cancer:1||sorafenib:1||stability:1||stomach:1||stomach neoplasms:1||subtypes:1||surgery:1||tasisulam:1||telomerase:1||telomere:1||thromboembolism:1||thymic epithelial tumour (TET):1||time to progression:1||tizanidine:1||trastuzumab:1||trastuzumabpkrb:1||treatment:1||tumor biomarkers:1||tumor heterogeneity:1||tumor microenvironment (TME):1||tumor mutation burden:1||tumor mutation burden  TMB:1||tumor purity:1||tumorinfiltrating lymphocytes:1||twodrug combination:1||tyrosine kinase inhibitors:1||urothelial carcinoma:1||vascular endothelial growth factor receptor 1:1||vascularized tumor spheroid:1||vitamin:1||wild type:1||young:1||zolbetuximab:1||2615669263:1||281318430:1||283237255:1||2832372556832:1||2832372581242:1||28397693573426:1||29814522218410229124:1||2987687237076502700:1||30min infusion:1||32823301468674327462:1||3282330626666279:1||3809220072:1||3809222447:1||38116380948:1||5Fluorouracil:1||5fluorouracil:1||613135237076502700:1||6131352443829:1||61322532489559979411285:1||613225325:1||61361564646852768:1||6137657304:1||7:1||78:1||ADARs:1||AKT:1||AML:1||AZD5363:1||Acquired resistance:1||Actionable genetic alteration:1||Acute myeloid leukemia:1||Adenocarcinoma of ampulla of Vater:1||Adjuvant CCRT:1||Adjuvant chemoradiotherapy:1||Adjuvant chemotherapy:1||Adjuvant treatment:1||Advanced hepatocellular carcinoma:1||Advanced nonsmall cell lung cancer:1||Advanced soft tissue sarcoma:1||Adverse event:1||Aflibercept:1||Aged:1||Alveolar soft part sarcoma:1||Ampliseq:1||And vascular endothelial growth factor receptor 2 (VEGFR2):1||Angiogenesis signature:1||Angiomyolipoma:1||Antiangiogenic agent:1||Antibodies:1||Anticancer:1||Anticancer drug:1||Anticoagulation:1||Asian:1||Asian patients:1||Asymptomatic brain metastases in NSCLC:1||Ataxia telangiectasia mutated (ATM):1||Avelumab:1||Awareness and willi:1||BEZ235:1||BIM deletion polymorphism:1||BRAF V600–mutant advanced melanoma:1||BRAF/EGFR inhibitor:1||BRAFV600E mutation:1||Beyond first progression:1||Biomedicine:1||Bone marrow:1||Bortezomib:1||Burkitt lymphoma:1||CJun:1||CA 199:1||CA199:1||CAPOX:1||CCNE1:1||CD133+:1||CD274:1||CD34:1||CD8:1||CDH1:1||CDK4:1||CHOP:1||CINV:1||CPT11:1||CT:1||CTNNB1:1||California Cancer Registry:1||Cancer clinical trial:1||Cancer genomics:1||Cancer immune activity:1||Cancer immunotherapy:1||Cancer stem cells:1||Capecitab:1||Carcinoma, Esophageal neoplasm:1||Carcinomatosis:1||Carcinosarcoma:1||Cellfree DNA (cfDNA):1||Cellular heterogeneity:1||Cerebrospinal fluid:1||Cerebrospinal fluid (CSF):1||Checkpoint inhibitor:1||Chemoradiation:1||Chromogranin A:1||Circulating tumor cell:1||Circulating tumor cells:1||Circulating tumor cells (CTCs):1||Cisplatinbased combination chemotherapy:1||Clinical subtypes:1||Clinical trial:1||Clinical trial phase II:1||Clinical trials:1||Colon cancer:1||Colonic neoplasms:1||Colorectal cancers:1||Colorectum:1||Combined modality therapy:1||Computational biology:1||Computed tomography:1||Concurrent chemoradiotherapy:1||Consensus subtype:1||Copy number alteration:1||Corneal epithelial change:1||Cytomegalovirus gastritis:1||Cytotoxic chemotherapy:1||DLL4:1||DNA:1||DNA damage:1||DNA sequencing:1||DP:1||DPYD:1||Derivatives:1||Dermatofibrosarcoma protuberans:1||Desmoid tumors:1||Desmoplastic small roundcell tumor:1||Diffuse:1||Digital image analysis:1||Digital sequencing:1||Dual blockade:1||EGFR inhibitor:1||EGFR/BRAF inhibitor:1||ERK:1||Editome:1||Efficacy:1||Elderly:1||Endocrine therapy:1||Epidemiology:1||Epidermal growth factor:1||Epidermal growth factor ointment:1||Epidermal growth factor receptor (EGFR):1||Epidermal growth factor receptor tyrosine kinase inhibitors:1||Epirubicin:1||Epithelialmesenchymal transition:1||EpsteinBarr Virus:1||EpsteinBarr virusassociated gastric cancer:1||ErbB2 receptor:1||Esophagogastric junction:1||Ethnic groups:1||Ewing sarcoma:1||Ewing&apos:1||Exon deletion:1||Expression:1||Extramammary Paget disease:1||FDG PET:1||FGFR inhibitor:1||FGFR2amplified:1||FGFR3TACC3:1||FLT3 amplification:1||FOLFIRI:1||Familial adenomatous polyposis:1||Family history:1||Female:1||Fibromatosis aggressive:1||Firstline:1||Firstline chemotherapy:1||Firstline palliative chemotherapy:1||Fluorescence in situ hybridization:1||Fluorouracil (FU):1||Fracture:1||GEPNEC:1||Gastric adenocarcinoma:1||Gastroenteropancreatic neuroendocrine tumor:1||Gastroenteropancreatic neuroendocrine carcinoma:1||Gastrointestinal stromal tumour:1||Gemcitabine failure:1||Genetic polymorphism:1||Genome:1||Genomic:1||Genomic analysis:1||Genomic profiling:1||Genomic test:1||Germ cell tumor:1||Glomerular filtration rate:1||Glycolysis:1||Glycoprotein:1||Granisetron:1||Guardant360:1||HER2 expression:1||HMGCoA reductase:1||HRD:1||Haptoglobin:1||Head and neck cancer:1||Hematogenous:1||Hemodialysis:1||Heparin:1||Hepatocellular:1||Hepatocellular carcinomas (HCC):1||Hepatocyte growth factor:1||Heterogeneity:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE